BioTelemetry, Inc. (BEAT) Reaches $33.15 After 4.00% Up Move; Blackrock LTD Duration Income Trust (BLW)’s Sentiment Is 0.92

January 14, 2018 - By Hazel Jackson

The stock increased 0.19% or $0.03 during the last trading session, reaching $16.04. About 77,734 shares traded. BlackRock Limited Duration Income Trust (BLW) has risen 7.11% since January 14, 2017 and is uptrending. It has underperformed by 9.59% the S&P500.

The stock of BioTelemetry, Inc. (NASDAQ:BEAT) is a huge mover today! The stock increased 4.91% or $1.55 during the last trading session, reaching $33.15. About 670,073 shares traded or 19.74% up from the average. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 87.79% since January 14, 2017 and is uptrending. It has outperformed by 71.09% the S&P500.The move comes after 8 months positive chart setup for the $1.07 billion company. It was reported on Jan, 14 by Barchart.com. We have $34.48 PT which if reached, will make NASDAQ:BEAT worth $42.96 million more.

Livingston Group Asset Management Co (Operating As Southport Capital Management) holds 0.53% of its portfolio in BlackRock Limited Duration Income Trust for 76,746 shares. Robinson Capital Management Llc owns 66,587 shares or 0.48% of their US portfolio. Moreover, Seabridge Investment Advisors Llc has 0.31% invested in the company for 82,815 shares. The California-based First Foundation Advisors has invested 0.3% in the stock. Rivernorth Capital Management Llc, a Illinois-based fund reported 227,204 shares.

Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on February, 28. They expect $0.21 EPS, up 16.67% or $0.03 from last year’s $0.18 per share. BEAT’s profit will be $6.80 million for 39.46 P/E if the $0.21 EPS becomes a reality. After $0.16 actual EPS reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts 31.25% EPS growth.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.07 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It has a 24.87 P/E ratio. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

Investors sentiment decreased to 1.28 in Q3 2017. Its down 0.02, from 1.3 in 2017Q2. It dived, as 15 investors sold BioTelemetry, Inc. shares while 66 reduced holdings. 41 funds opened positions while 63 raised stakes. 25.49 million shares or 7.15% more from 23.79 million shares in 2017Q2 were reported. Perkins Capital Mgmt Inc reported 0.52% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Alps Advisors Inc, a Colorado-based fund reported 12,429 shares. Cambridge Invest Research Advsrs reported 8,728 shares. Premier Asset Mgmt, Illinois-based fund reported 7,170 shares. Pinebridge Investments Lp has 3,815 shares for 0% of their portfolio. Farmers And Merchants accumulated 257 shares. Louisiana State Employees Retirement invested in 0.02% or 12,500 shares. Tiaa Cref Inv Mgmt Ltd Liability Company accumulated 161,364 shares. Alliancebernstein Limited Partnership owns 37,500 shares. Bancorporation Of America De, a North Carolina-based fund reported 369,928 shares. Macquarie Gru has invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Secor Cap Advisors Limited Partnership holds 0.14% in BioTelemetry, Inc. (NASDAQ:BEAT) or 44,984 shares. Manufacturers Life Ins The has invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Mckinley Capital Mgmt Limited Liability Corp Delaware invested in 157,795 shares or 0.21% of the stock. Psagot Inv House Limited reported 22,350 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>